Our guest on this ALCSI podcast is Jill Feldman. Jill is a lung cancer patient and advocate. With an extensive family history of lung cancer, Jill got involved in lung cancer advocacy in 2001, when it was in its infancy. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR-positive lung cancer.

Jill is committed to understanding and promoting patient-centered research as Chair of IASLC’s patient advisory board, a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, and as the patient advocate on the National Lung Cancer Round Table steering committee. In addition, she is a co-founder of the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFR lung cancer. Jill serves in various other leadership roles to improve the speed and quality of research and uses her voice and privilege to embed a health equity lens in all aspects of research and care.

Your podcast hosts are Priyanka Senthil, Pranav Mandyam, and Sam Schwartz.

Lung cancer is the leading cause of cancer death in the world. Large clinical trials have shown that lung cancer screening through low-dose computed tomography (CT) reduces lung cancer mortality by up to 33%. In fact, if every high-risk American were to get screened right now, thousands of lives could be saved this year alone. However, less than 5% of high-risk Americans are currently getting screened. Visit our website at https://www.alcsi.org/ for free educational resources and webinars on lung cancer and lung cancer screening.

Email: info@alcsi.org

Twitter: @AmLungCSI

Instagram: @amlungcsi